Epidemiology of chronic myeloid leukaemia: an update
M Höglund, F Sandin, B Simonsson - Annals of hematology, 2015 - Springer
National and regional population-based registries are, provided diagnostic accuracy and full
coverage of the target population, indispensible tools for epidemiological research. Chronic …
coverage of the target population, indispensible tools for epidemiological research. Chronic …
Chronic myeloid leukemia in India
P Ganesan, L Kumar - Journal of global oncology, 2017 - ascopubs.org
Background In the last decade, the use of imatinib has brought a paradigm shift in the
management of chronic myeloid leukemia (CML). In India, imatinib has been available for …
management of chronic myeloid leukemia (CML). In India, imatinib has been available for …
[HTML][HTML] Global, regional, and national burden of chronic myeloid leukemia, 1990–2017: a systematic analysis for the global burden of disease study 2017
Q Lin, L Mao, L Shao, L Zhu, Q Han, H Zhu, J Jin… - Frontiers in …, 2020 - frontiersin.org
Background With the advent of tyrosine kinase inhibitors (TKIs), the prognosis of chronic
myeloid leukemia (CML) seems to have dramatically improved over the last two decades …
myeloid leukemia (CML) seems to have dramatically improved over the last two decades …
Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia
Q Jiang, ZC Liu, SX Zhang, RP Gale - Journal of cancer research and …, 2016 - Springer
Purpose To explore therapy-goals and patients' expectations regarding discontinuing
tyrosine kinase inhibitors (TKIs) therapy in Chinese with chronic myeloid leukemia (CML). To …
tyrosine kinase inhibitors (TKIs) therapy in Chinese with chronic myeloid leukemia (CML). To …
[HTML][HTML] Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
SH Kim, H Menon, S Jootar, T Saikia, JY Kwak… - …, 2014 - ncbi.nlm.nih.gov
Abstract Radotinib (IY5511HCL), a novel and selective BCR-ABL1 tyrosine kinase inhibitor,
has shown pre-clinical and phase I activity and safety in chronic myeloid leukemia. This …
has shown pre-clinical and phase I activity and safety in chronic myeloid leukemia. This …
[HTML][HTML] Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase
L Yu, J Liu, X Huang, Q Jiang - Scientific Reports, 2019 - nature.com
To explore the differences in glucose-lipid metabolism profiles among the 3 TKIs, we
designed a retrospective study to compare the onset of hyperglycaemia …
designed a retrospective study to compare the onset of hyperglycaemia …
Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report
H Nakamae, S Fujisawa, M Ogura, T Uchida… - International journal of …, 2017 - Springer
The international phase III DASISION trial demonstrated improved efficacy of dasatinib
versus imatinib in treatment-naive patients with chronic myeloid leukemia in the chronic …
versus imatinib in treatment-naive patients with chronic myeloid leukemia in the chronic …
MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis
Background: MDR1 gene polymorphisms were demonstrated to be associated with
interindividual variability of imatinib response for chronic myeloid leukemia (CML) patients in …
interindividual variability of imatinib response for chronic myeloid leukemia (CML) patients in …
[HTML][HTML] Health-related quality of life using EQ-5D among chronic myeloid leukaemia patients in health centres in Klang Valley, Malaysia
Chronic Myeloid Leukaemia (CML) responds well with the targeted therapy drugs, Tyrosine
Kinase Inhibitors (TKI), that give potentially long-term disease control for the patients. The …
Kinase Inhibitors (TKI), that give potentially long-term disease control for the patients. The …
[HTML][HTML] Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological …
T Beinortas, I Tavorienė, T Žvirblis, R Gerbutavičius… - BMC cancer, 2016 - Springer
Background Currently available chronic myeloid leukaemia (CML) survival reports have
originated from more affluent countries. Herein we report the entire country data on …
originated from more affluent countries. Herein we report the entire country data on …